|
Castle Biosciences ، Inc. (CSTL) DCF تقييم
US | Healthcare | Medical - Diagnostics & Research | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Castle Biosciences, Inc. (CSTL) Bundle
اكتشف الإمكانات الحقيقية لـ Castle Biosciences ، Inc. (CSTL) مع حاسبة DCF المتقدمة! اضبط الافتراضات الهامة واستكشاف السيناريوهات المختلفة وتقييم كيفية تأثير التغييرات المختلفة على تقييم Castle Biosciences ، Inc. (CSTL) - كل ذلك ضمن قالب Excel واحد مريح.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 62.6 | 94.1 | 137.0 | 219.8 | 332.1 | 504.2 | 765.5 | 1,162.2 | 1,764.4 | 2,678.9 |
| Revenue Growth, % | 0 | 50.18 | 45.65 | 60.38 | 51.09 | 51.83 | 51.83 | 51.83 | 51.83 | 51.83 |
| EBITDA | -7.1 | -36.6 | -58.3 | -45.0 | 38.1 | -102.7 | -155.9 | -236.6 | -359.3 | -545.4 |
| EBITDA, % | -11.32 | -38.91 | -42.57 | -20.49 | 11.48 | -20.36 | -20.36 | -20.36 | -20.36 | -20.36 |
| Depreciation | .5 | 3.4 | 10.5 | 12.3 | 16.0 | 22.7 | 34.4 | 52.3 | 79.4 | 120.5 |
| Depreciation, % | 0.7534 | 3.62 | 7.69 | 5.61 | 4.82 | 4.5 | 4.5 | 4.5 | 4.5 | 4.5 |
| EBIT | -7.6 | -40.0 | -68.9 | -57.4 | 22.1 | -125.3 | -190.3 | -288.9 | -438.6 | -666.0 |
| EBIT, % | -12.08 | -42.53 | -50.27 | -26.1 | 6.67 | -24.86 | -24.86 | -24.86 | -24.86 | -24.86 |
| Total Cash | 409.9 | 329.6 | 258.6 | 243.1 | 293.1 | 492.3 | 747.5 | 1,134.9 | 1,723.1 | 2,616.0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 12.8 | 17.3 | 23.5 | 38.3 | 51.2 | 89.5 | 135.8 | 206.2 | 313.1 | 475.3 |
| Account Receivables, % | 20.37 | 18.37 | 17.13 | 17.43 | 15.42 | 17.74 | 17.74 | 17.74 | 17.74 | 17.74 |
| Inventories | 2.2 | 2.0 | 4.0 | 7.9 | 8.1 | 14.8 | 22.4 | 34.1 | 51.7 | 78.5 |
| Inventories, % | 3.54 | 2.15 | 2.9 | 3.61 | 2.45 | 2.93 | 2.93 | 2.93 | 2.93 | 2.93 |
| Accounts Payable | 2.1 | 2.5 | 4.7 | 10.3 | 6.9 | 16.4 | 24.9 | 37.8 | 57.4 | 87.1 |
| Accounts Payable, % | 3.35 | 2.71 | 3.45 | 4.67 | 2.08 | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 |
| Capital Expenditure | -4.8 | -3.5 | -5.6 | -13.6 | -28.3 | -30.4 | -46.1 | -70.0 | -106.3 | -161.4 |
| Capital Expenditure, % | -7.58 | -3.7 | -4.11 | -6.2 | -8.53 | -6.02 | -6.02 | -6.02 | -6.02 | -6.02 |
| Tax Rate, % | 15.39 | 15.39 | 15.39 | 15.39 | 15.39 | 15.39 | 15.39 | 15.39 | 15.39 | 15.39 |
| EBITAT | -7.6 | -31.3 | -67.1 | -57.5 | 18.7 | -115.4 | -175.2 | -265.9 | -403.8 | -613.0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -24.8 | -35.2 | -68.2 | -72.0 | -10.1 | -158.4 | -232.4 | -352.8 | -535.6 | -813.2 |
| WACC, % | 8.15 | 8.11 | 8.15 | 8.15 | 8.12 | 8.14 | 8.14 | 8.14 | 8.14 | 8.14 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1,565.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -829 | |||||||||
| Terminal Value | -13,517 | |||||||||
| Present Terminal Value | -9,141 | |||||||||
| Enterprise Value | -10,707 | |||||||||
| Net Debt | -93 | |||||||||
| Equity Value | -10,614 | |||||||||
| Diluted Shares Outstanding, MM | 29 | |||||||||
| Equity Value Per Share | -362.81 |
What You Will Get
- Real CSTL Financial Data: Pre-filled with Castle Biosciences' historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Castle Biosciences' intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- 🔍 Real-Life CSTL Financials: Pre-filled historical and projected data for Castle Biosciences, Inc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Castle Biosciences’ intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Castle Biosciences’ valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Castle Biosciences, Inc. (CSTL) data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Castle Biosciences, Inc. (CSTL)’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Castle Biosciences, Inc. (CSTL)?
- Accurate Data: Up-to-date Castle Biosciences financials provide trustworthy valuation outcomes.
- Customizable: Tailor essential parameters such as growth rates, WACC, and tax rates to fit your forecasts.
- Time-Saving: Ready-to-use calculations save you from starting from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Simple design and guided instructions make it accessible for all users.
Who Should Use This Product?
- Investors: Evaluate Castle Biosciences’ valuation before making investment decisions.
- CFOs and Financial Analysts: Enhance valuation methodologies and validate financial forecasts.
- Startup Founders: Understand how biotech companies like Castle Biosciences are appraised.
- Consultants: Provide expert valuation analyses and reports for clients in the healthcare sector.
- Students and Educators: Utilize real-life data to learn and teach valuation principles in biotechnology.
What the Template Contains
- Pre-Filled DCF Model: Castle Biosciences’ financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Castle Biosciences’ profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.